Skip to content

Effects of preoperative conformal radiotherapy combined with precision centripetalism resection for the hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomised controlled t

Effects of preoperative conformal radiotherapy combined with precision centripetalism resection for the hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomised controlled t

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-11001708
Enrollment
Unknown
Registered
2011-11-11
Start date
2011-11-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary liver cancer

Interventions

A:preoperative conformal radiotherapy combined with precision centripetalism resection
B:precision centripetalism resection

Sponsors

Eastern Hepatobiliary Surgical Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. 20 to 70 years old male or non-pregnant female hepatocellular carcinoma patient; 2. Portal vein tumor thrombus, I, II, III-type (Cheng SQ, et al. Hepato-Gastroenterology 2007; 54: 499-502); 3. Pathologically proved HCC, single tumor <10cm in diameter, without extrahepatic metastasis or adjacent organ involvement before surgery; 4. BCLC stage is either A or B, liver function is Child-Pugh A or B; 5. No apparent abnormality of the heart, lung, and kidney; 6. No HCV, HIV and syphilis infection; 7. Patients should sign the informed consent of this study.

Exclusion criteria

Exclusion criteria: 1. If preoperative liver function is Child C, it cannot tolerate conformal radiotherapy; 2. With evidence of extrahepatic metastasis; 3. With evidence of unstable angina pectoris, symptomatic congestive heart failure, severe arrhythmia, acute myocardial infarction within the last six months, prolonged QT interval (>450ms); 4. Malignant or metastatic tumor in other sites in last 5 years; 5. Patients can not be followed-up regularly; 6. Patients participating in other trials.

Design outcomes

Primary

MeasureTime frame
Overall survival;Recurrent rates and Survival rates in 1,2 year;Volume of bleeding;

Secondary

MeasureTime frame
radiographic parameters;Liver function afer hepatectom;

Countries

China

Contacts

Public ContactChengshuqun
chengshuqun@yahoo.com.cn+86 021 81875251

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026